News & Presentations

Umoja Biopharma Launches with $53M Series A Financing to Develop Fully Integrated, Scalable, In Vivo Immunotherapy Platform
November 18, 2020

Umoja’s platform addresses key limitations of existing engineered immunotherapies. Company backed by prominent life science investors MPM Capital, DCVC Bio and Qiming Venture Partners USA and led by an experienced team of scientist/entrepreneurs.


We are led by a world class team that operates on a foundation of respect for the contributions of everyone on the Umoja team.